nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—CYP3A4—Tamoxifen—pancreatic cancer	0.0323	0.24	CbGbCtD
Salbutamol—CYP3A4—Erlotinib—pancreatic cancer	0.0274	0.204	CbGbCtD
Salbutamol—CYP3A4—Irinotecan—pancreatic cancer	0.0248	0.185	CbGbCtD
Salbutamol—CYP3A4—Docetaxel—pancreatic cancer	0.0182	0.135	CbGbCtD
Salbutamol—CYP3A4—Sunitinib—pancreatic cancer	0.0181	0.135	CbGbCtD
Salbutamol—CYP3A4—Doxorubicin—pancreatic cancer	0.0135	0.101	CbGbCtD
Salbutamol—Clenbuterol—TNF—pancreatic cancer	0.00339	0.704	CrCbGaD
Salbutamol—Epinephrine—TNF—pancreatic cancer	0.00142	0.296	CrCbGaD
Salbutamol—Headache—Sunitinib—pancreatic cancer	0.00063	0.000769	CcSEcCtD
Salbutamol—Syncope—Docetaxel—pancreatic cancer	0.000629	0.000768	CcSEcCtD
Salbutamol—Asthma—Doxorubicin—pancreatic cancer	0.000629	0.000768	CcSEcCtD
Salbutamol—Influenza—Doxorubicin—pancreatic cancer	0.000629	0.000768	CcSEcCtD
Salbutamol—Body temperature increased—Fluorouracil—pancreatic cancer	0.000627	0.000766	CcSEcCtD
Salbutamol—Palpitations—Docetaxel—pancreatic cancer	0.00062	0.000757	CcSEcCtD
Salbutamol—Loss of consciousness—Docetaxel—pancreatic cancer	0.000617	0.000753	CcSEcCtD
Salbutamol—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000613	0.000748	CcSEcCtD
Salbutamol—Cough—Docetaxel—pancreatic cancer	0.000612	0.000748	CcSEcCtD
Salbutamol—Angina pectoris—Doxorubicin—pancreatic cancer	0.000612	0.000748	CcSEcCtD
Salbutamol—Hypersensitivity—Irinotecan—pancreatic cancer	0.00061	0.000745	CcSEcCtD
Salbutamol—Hypertension—Docetaxel—pancreatic cancer	0.000606	0.00074	CcSEcCtD
Salbutamol—Drowsiness—Epirubicin—pancreatic cancer	0.000606	0.00074	CcSEcCtD
Salbutamol—Bronchitis—Doxorubicin—pancreatic cancer	0.000604	0.000738	CcSEcCtD
Salbutamol—Myalgia—Docetaxel—pancreatic cancer	0.000597	0.00073	CcSEcCtD
Salbutamol—Arthralgia—Docetaxel—pancreatic cancer	0.000597	0.00073	CcSEcCtD
Salbutamol—Chest pain—Docetaxel—pancreatic cancer	0.000597	0.00073	CcSEcCtD
Salbutamol—Nausea—Sunitinib—pancreatic cancer	0.000597	0.00073	CcSEcCtD
Salbutamol—Asthenia—Irinotecan—pancreatic cancer	0.000594	0.000726	CcSEcCtD
Salbutamol—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000594	0.000725	CcSEcCtD
Salbutamol—Jaundice—Epirubicin—pancreatic cancer	0.00059	0.000721	CcSEcCtD
Salbutamol—Stomatitis—Epirubicin—pancreatic cancer	0.00059	0.000721	CcSEcCtD
Salbutamol—Urinary tract infection—Epirubicin—pancreatic cancer	0.000589	0.000719	CcSEcCtD
Salbutamol—Conjunctivitis—Epirubicin—pancreatic cancer	0.000589	0.000719	CcSEcCtD
Salbutamol—Dysuria—Doxorubicin—pancreatic cancer	0.000588	0.000718	CcSEcCtD
Salbutamol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000585	0.000714	CcSEcCtD
Salbutamol—Dry mouth—Docetaxel—pancreatic cancer	0.000584	0.000714	CcSEcCtD
Salbutamol—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000584	0.000713	CcSEcCtD
Salbutamol—Sweating—Epirubicin—pancreatic cancer	0.000581	0.000709	CcSEcCtD
Salbutamol—Asthenia—Gemcitabine—pancreatic cancer	0.000579	0.000707	CcSEcCtD
Salbutamol—Haematuria—Epirubicin—pancreatic cancer	0.000577	0.000705	CcSEcCtD
Salbutamol—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000573	0.000699	CcSEcCtD
Salbutamol—Oedema—Docetaxel—pancreatic cancer	0.000573	0.000699	CcSEcCtD
Salbutamol—Epistaxis—Epirubicin—pancreatic cancer	0.000571	0.000698	CcSEcCtD
Salbutamol—Pruritus—Gemcitabine—pancreatic cancer	0.000571	0.000697	CcSEcCtD
Salbutamol—Infection—Docetaxel—pancreatic cancer	0.000569	0.000695	CcSEcCtD
Salbutamol—Sinusitis—Epirubicin—pancreatic cancer	0.000568	0.000694	CcSEcCtD
Salbutamol—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000567	0.000692	CcSEcCtD
Salbutamol—Diarrhoea—Irinotecan—pancreatic cancer	0.000567	0.000692	CcSEcCtD
Salbutamol—Shock—Docetaxel—pancreatic cancer	0.000563	0.000688	CcSEcCtD
Salbutamol—Nervous system disorder—Docetaxel—pancreatic cancer	0.000562	0.000686	CcSEcCtD
Salbutamol—Pruritus—Fluorouracil—pancreatic cancer	0.000561	0.000686	CcSEcCtD
Salbutamol—Drowsiness—Doxorubicin—pancreatic cancer	0.00056	0.000684	CcSEcCtD
Salbutamol—Tachycardia—Docetaxel—pancreatic cancer	0.000559	0.000683	CcSEcCtD
Salbutamol—Skin disorder—Docetaxel—pancreatic cancer	0.000556	0.000679	CcSEcCtD
Salbutamol—Diarrhoea—Gemcitabine—pancreatic cancer	0.000552	0.000674	CcSEcCtD
Salbutamol—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000549	0.000671	CcSEcCtD
Salbutamol—Dizziness—Irinotecan—pancreatic cancer	0.000548	0.000669	CcSEcCtD
Salbutamol—Haemoglobin—Epirubicin—pancreatic cancer	0.000546	0.000667	CcSEcCtD
Salbutamol—Jaundice—Doxorubicin—pancreatic cancer	0.000546	0.000667	CcSEcCtD
Salbutamol—Stomatitis—Doxorubicin—pancreatic cancer	0.000546	0.000667	CcSEcCtD
Salbutamol—Anorexia—Docetaxel—pancreatic cancer	0.000546	0.000667	CcSEcCtD
Salbutamol—Rhinitis—Epirubicin—pancreatic cancer	0.000545	0.000666	CcSEcCtD
Salbutamol—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000545	0.000665	CcSEcCtD
Salbutamol—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000545	0.000665	CcSEcCtD
Salbutamol—Haemorrhage—Epirubicin—pancreatic cancer	0.000544	0.000664	CcSEcCtD
Salbutamol—Diarrhoea—Fluorouracil—pancreatic cancer	0.000543	0.000663	CcSEcCtD
Salbutamol—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000541	0.000661	CcSEcCtD
Salbutamol—Pharyngitis—Epirubicin—pancreatic cancer	0.00054	0.000659	CcSEcCtD
Salbutamol—Sweating—Doxorubicin—pancreatic cancer	0.000537	0.000656	CcSEcCtD
Salbutamol—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000537	0.000656	CcSEcCtD
Salbutamol—Hypotension—Docetaxel—pancreatic cancer	0.000535	0.000654	CcSEcCtD
Salbutamol—Haematuria—Doxorubicin—pancreatic cancer	0.000534	0.000653	CcSEcCtD
Salbutamol—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000534	0.000652	CcSEcCtD
Salbutamol—Urethral disorder—Epirubicin—pancreatic cancer	0.000533	0.000651	CcSEcCtD
Salbutamol—Epistaxis—Doxorubicin—pancreatic cancer	0.000529	0.000646	CcSEcCtD
Salbutamol—Vomiting—Irinotecan—pancreatic cancer	0.000527	0.000643	CcSEcCtD
Salbutamol—Sinusitis—Doxorubicin—pancreatic cancer	0.000526	0.000642	CcSEcCtD
Salbutamol—Dizziness—Fluorouracil—pancreatic cancer	0.000525	0.000641	CcSEcCtD
Salbutamol—Rash—Irinotecan—pancreatic cancer	0.000522	0.000638	CcSEcCtD
Salbutamol—Dermatitis—Irinotecan—pancreatic cancer	0.000522	0.000637	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000522	0.000637	CcSEcCtD
Salbutamol—Headache—Irinotecan—pancreatic cancer	0.000519	0.000634	CcSEcCtD
Salbutamol—Insomnia—Docetaxel—pancreatic cancer	0.000518	0.000633	CcSEcCtD
Salbutamol—Paraesthesia—Docetaxel—pancreatic cancer	0.000514	0.000628	CcSEcCtD
Salbutamol—Vomiting—Gemcitabine—pancreatic cancer	0.000513	0.000627	CcSEcCtD
Salbutamol—Dyspnoea—Docetaxel—pancreatic cancer	0.000511	0.000624	CcSEcCtD
Salbutamol—Somnolence—Docetaxel—pancreatic cancer	0.000509	0.000622	CcSEcCtD
Salbutamol—Rash—Gemcitabine—pancreatic cancer	0.000509	0.000621	CcSEcCtD
Salbutamol—Dermatitis—Gemcitabine—pancreatic cancer	0.000508	0.000621	CcSEcCtD
Salbutamol—Tinnitus—Epirubicin—pancreatic cancer	0.000507	0.000619	CcSEcCtD
Salbutamol—Haemoglobin—Doxorubicin—pancreatic cancer	0.000506	0.000617	CcSEcCtD
Salbutamol—Headache—Gemcitabine—pancreatic cancer	0.000506	0.000617	CcSEcCtD
Salbutamol—Cardiac disorder—Epirubicin—pancreatic cancer	0.000505	0.000616	CcSEcCtD
Salbutamol—Flushing—Epirubicin—pancreatic cancer	0.000505	0.000616	CcSEcCtD
Salbutamol—Vomiting—Fluorouracil—pancreatic cancer	0.000504	0.000616	CcSEcCtD
Salbutamol—Rhinitis—Doxorubicin—pancreatic cancer	0.000504	0.000616	CcSEcCtD
Salbutamol—Dyspepsia—Docetaxel—pancreatic cancer	0.000504	0.000616	CcSEcCtD
Salbutamol—Haemorrhage—Doxorubicin—pancreatic cancer	0.000503	0.000614	CcSEcCtD
Salbutamol—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000501	0.000611	CcSEcCtD
Salbutamol—Rash—Fluorouracil—pancreatic cancer	0.0005	0.000611	CcSEcCtD
Salbutamol—Dermatitis—Fluorouracil—pancreatic cancer	0.0005	0.00061	CcSEcCtD
Salbutamol—Pharyngitis—Doxorubicin—pancreatic cancer	0.000499	0.00061	CcSEcCtD
Salbutamol—Decreased appetite—Docetaxel—pancreatic cancer	0.000498	0.000608	CcSEcCtD
Salbutamol—Headache—Fluorouracil—pancreatic cancer	0.000497	0.000607	CcSEcCtD
Salbutamol—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000497	0.000607	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000494	0.000604	CcSEcCtD
Salbutamol—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000494	0.000604	CcSEcCtD
Salbutamol—Fatigue—Docetaxel—pancreatic cancer	0.000494	0.000603	CcSEcCtD
Salbutamol—Angiopathy—Epirubicin—pancreatic cancer	0.000493	0.000602	CcSEcCtD
Salbutamol—Urethral disorder—Doxorubicin—pancreatic cancer	0.000493	0.000602	CcSEcCtD
Salbutamol—Nausea—Irinotecan—pancreatic cancer	0.000492	0.000601	CcSEcCtD
Salbutamol—Immune system disorder—Epirubicin—pancreatic cancer	0.000491	0.0006	CcSEcCtD
Salbutamol—Mediastinal disorder—Epirubicin—pancreatic cancer	0.00049	0.000598	CcSEcCtD
Salbutamol—Pain—Docetaxel—pancreatic cancer	0.00049	0.000598	CcSEcCtD
Salbutamol—Constipation—Docetaxel—pancreatic cancer	0.00049	0.000598	CcSEcCtD
Salbutamol—Chills—Epirubicin—pancreatic cancer	0.000488	0.000596	CcSEcCtD
Salbutamol—Arrhythmia—Epirubicin—pancreatic cancer	0.000486	0.000593	CcSEcCtD
Salbutamol—Nausea—Gemcitabine—pancreatic cancer	0.000479	0.000585	CcSEcCtD
Salbutamol—Mental disorder—Epirubicin—pancreatic cancer	0.000476	0.000582	CcSEcCtD
Salbutamol—Malnutrition—Epirubicin—pancreatic cancer	0.000473	0.000578	CcSEcCtD
Salbutamol—Feeling abnormal—Docetaxel—pancreatic cancer	0.000472	0.000576	CcSEcCtD
Salbutamol—Nausea—Fluorouracil—pancreatic cancer	0.000471	0.000576	CcSEcCtD
Salbutamol—Tinnitus—Doxorubicin—pancreatic cancer	0.000469	0.000573	CcSEcCtD
Salbutamol—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000468	0.000572	CcSEcCtD
Salbutamol—Flushing—Doxorubicin—pancreatic cancer	0.000467	0.00057	CcSEcCtD
Salbutamol—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000467	0.00057	CcSEcCtD
Salbutamol—Flatulence—Epirubicin—pancreatic cancer	0.000466	0.00057	CcSEcCtD
Salbutamol—Tension—Epirubicin—pancreatic cancer	0.000464	0.000567	CcSEcCtD
Salbutamol—Dysgeusia—Epirubicin—pancreatic cancer	0.000463	0.000566	CcSEcCtD
Salbutamol—Nervousness—Epirubicin—pancreatic cancer	0.00046	0.000561	CcSEcCtD
Salbutamol—Back pain—Epirubicin—pancreatic cancer	0.000458	0.000559	CcSEcCtD
Salbutamol—Angiopathy—Doxorubicin—pancreatic cancer	0.000456	0.000557	CcSEcCtD
Salbutamol—Muscle spasms—Epirubicin—pancreatic cancer	0.000455	0.000556	CcSEcCtD
Salbutamol—Immune system disorder—Doxorubicin—pancreatic cancer	0.000454	0.000555	CcSEcCtD
Salbutamol—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000453	0.000554	CcSEcCtD
Salbutamol—Abdominal pain—Docetaxel—pancreatic cancer	0.000453	0.000553	CcSEcCtD
Salbutamol—Body temperature increased—Docetaxel—pancreatic cancer	0.000453	0.000553	CcSEcCtD
Salbutamol—Chills—Doxorubicin—pancreatic cancer	0.000451	0.000551	CcSEcCtD
Salbutamol—Arrhythmia—Doxorubicin—pancreatic cancer	0.000449	0.000549	CcSEcCtD
Salbutamol—Mental disorder—Doxorubicin—pancreatic cancer	0.000441	0.000538	CcSEcCtD
Salbutamol—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000439	0.000536	CcSEcCtD
Salbutamol—Malnutrition—Doxorubicin—pancreatic cancer	0.000438	0.000535	CcSEcCtD
Salbutamol—Agitation—Epirubicin—pancreatic cancer	0.000435	0.000531	CcSEcCtD
Salbutamol—Flatulence—Doxorubicin—pancreatic cancer	0.000432	0.000527	CcSEcCtD
Salbutamol—Tension—Doxorubicin—pancreatic cancer	0.00043	0.000525	CcSEcCtD
Salbutamol—Dysgeusia—Doxorubicin—pancreatic cancer	0.000429	0.000524	CcSEcCtD
Salbutamol—Malaise—Epirubicin—pancreatic cancer	0.000427	0.000521	CcSEcCtD
Salbutamol—Nervousness—Doxorubicin—pancreatic cancer	0.000425	0.000519	CcSEcCtD
Salbutamol—Vertigo—Epirubicin—pancreatic cancer	0.000425	0.000519	CcSEcCtD
Salbutamol—Syncope—Epirubicin—pancreatic cancer	0.000424	0.000518	CcSEcCtD
Salbutamol—Back pain—Doxorubicin—pancreatic cancer	0.000424	0.000517	CcSEcCtD
Salbutamol—Hypersensitivity—Docetaxel—pancreatic cancer	0.000422	0.000515	CcSEcCtD
Salbutamol—Muscle spasms—Doxorubicin—pancreatic cancer	0.000421	0.000514	CcSEcCtD
Salbutamol—Palpitations—Epirubicin—pancreatic cancer	0.000418	0.000511	CcSEcCtD
Salbutamol—Loss of consciousness—Epirubicin—pancreatic cancer	0.000416	0.000508	CcSEcCtD
Salbutamol—Cough—Epirubicin—pancreatic cancer	0.000413	0.000504	CcSEcCtD
Salbutamol—Asthenia—Docetaxel—pancreatic cancer	0.000411	0.000502	CcSEcCtD
Salbutamol—Hypertension—Epirubicin—pancreatic cancer	0.000409	0.000499	CcSEcCtD
Salbutamol—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000406	0.000496	CcSEcCtD
Salbutamol—Pruritus—Docetaxel—pancreatic cancer	0.000405	0.000495	CcSEcCtD
Salbutamol—Myalgia—Epirubicin—pancreatic cancer	0.000403	0.000492	CcSEcCtD
Salbutamol—Arthralgia—Epirubicin—pancreatic cancer	0.000403	0.000492	CcSEcCtD
Salbutamol—Chest pain—Epirubicin—pancreatic cancer	0.000403	0.000492	CcSEcCtD
Salbutamol—Agitation—Doxorubicin—pancreatic cancer	0.000402	0.000491	CcSEcCtD
Salbutamol—Anxiety—Epirubicin—pancreatic cancer	0.000402	0.00049	CcSEcCtD
Salbutamol—Discomfort—Epirubicin—pancreatic cancer	0.000398	0.000486	CcSEcCtD
Salbutamol—Malaise—Doxorubicin—pancreatic cancer	0.000395	0.000482	CcSEcCtD
Salbutamol—Dry mouth—Epirubicin—pancreatic cancer	0.000394	0.000481	CcSEcCtD
Salbutamol—Vertigo—Doxorubicin—pancreatic cancer	0.000393	0.00048	CcSEcCtD
Salbutamol—Syncope—Doxorubicin—pancreatic cancer	0.000393	0.00048	CcSEcCtD
Salbutamol—Diarrhoea—Docetaxel—pancreatic cancer	0.000392	0.000479	CcSEcCtD
Salbutamol—Palpitations—Doxorubicin—pancreatic cancer	0.000387	0.000473	CcSEcCtD
Salbutamol—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000386	0.000472	CcSEcCtD
Salbutamol—Oedema—Epirubicin—pancreatic cancer	0.000386	0.000472	CcSEcCtD
Salbutamol—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000385	0.00047	CcSEcCtD
Salbutamol—Infection—Epirubicin—pancreatic cancer	0.000384	0.000469	CcSEcCtD
Salbutamol—Cough—Doxorubicin—pancreatic cancer	0.000382	0.000467	CcSEcCtD
Salbutamol—Shock—Epirubicin—pancreatic cancer	0.00038	0.000464	CcSEcCtD
Salbutamol—Nervous system disorder—Epirubicin—pancreatic cancer	0.000379	0.000463	CcSEcCtD
Salbutamol—Dizziness—Docetaxel—pancreatic cancer	0.000379	0.000462	CcSEcCtD
Salbutamol—Hypertension—Doxorubicin—pancreatic cancer	0.000378	0.000462	CcSEcCtD
Salbutamol—Tachycardia—Epirubicin—pancreatic cancer	0.000377	0.00046	CcSEcCtD
Salbutamol—Skin disorder—Epirubicin—pancreatic cancer	0.000375	0.000458	CcSEcCtD
Salbutamol—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000373	0.000456	CcSEcCtD
Salbutamol—Arthralgia—Doxorubicin—pancreatic cancer	0.000373	0.000455	CcSEcCtD
Salbutamol—Myalgia—Doxorubicin—pancreatic cancer	0.000373	0.000455	CcSEcCtD
Salbutamol—Chest pain—Doxorubicin—pancreatic cancer	0.000373	0.000455	CcSEcCtD
Salbutamol—Anxiety—Doxorubicin—pancreatic cancer	0.000372	0.000454	CcSEcCtD
Salbutamol—Discomfort—Doxorubicin—pancreatic cancer	0.000368	0.00045	CcSEcCtD
Salbutamol—Anorexia—Epirubicin—pancreatic cancer	0.000368	0.00045	CcSEcCtD
Salbutamol—Dry mouth—Doxorubicin—pancreatic cancer	0.000365	0.000445	CcSEcCtD
Salbutamol—Vomiting—Docetaxel—pancreatic cancer	0.000364	0.000445	CcSEcCtD
Salbutamol—Rash—Docetaxel—pancreatic cancer	0.000361	0.000441	CcSEcCtD
Salbutamol—Hypotension—Epirubicin—pancreatic cancer	0.000361	0.000441	CcSEcCtD
Salbutamol—Dermatitis—Docetaxel—pancreatic cancer	0.000361	0.000441	CcSEcCtD
Salbutamol—Headache—Docetaxel—pancreatic cancer	0.000359	0.000438	CcSEcCtD
Salbutamol—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000357	0.000436	CcSEcCtD
Salbutamol—Oedema—Doxorubicin—pancreatic cancer	0.000357	0.000436	CcSEcCtD
Salbutamol—Infection—Doxorubicin—pancreatic cancer	0.000355	0.000434	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000352	0.00043	CcSEcCtD
Salbutamol—Shock—Doxorubicin—pancreatic cancer	0.000352	0.000429	CcSEcCtD
Salbutamol—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000351	0.000428	CcSEcCtD
Salbutamol—Insomnia—Epirubicin—pancreatic cancer	0.000349	0.000427	CcSEcCtD
Salbutamol—Tachycardia—Doxorubicin—pancreatic cancer	0.000349	0.000426	CcSEcCtD
Salbutamol—Skin disorder—Doxorubicin—pancreatic cancer	0.000347	0.000424	CcSEcCtD
Salbutamol—Paraesthesia—Epirubicin—pancreatic cancer	0.000347	0.000424	CcSEcCtD
Salbutamol—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000346	0.000422	CcSEcCtD
Salbutamol—Dyspnoea—Epirubicin—pancreatic cancer	0.000344	0.000421	CcSEcCtD
Salbutamol—Somnolence—Epirubicin—pancreatic cancer	0.000343	0.000419	CcSEcCtD
Salbutamol—Anorexia—Doxorubicin—pancreatic cancer	0.000341	0.000416	CcSEcCtD
Salbutamol—Nausea—Docetaxel—pancreatic cancer	0.00034	0.000415	CcSEcCtD
Salbutamol—Dyspepsia—Epirubicin—pancreatic cancer	0.00034	0.000415	CcSEcCtD
Salbutamol—Decreased appetite—Epirubicin—pancreatic cancer	0.000336	0.00041	CcSEcCtD
Salbutamol—Hypotension—Doxorubicin—pancreatic cancer	0.000334	0.000408	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000333	0.000407	CcSEcCtD
Salbutamol—Fatigue—Epirubicin—pancreatic cancer	0.000333	0.000407	CcSEcCtD
Salbutamol—Constipation—Epirubicin—pancreatic cancer	0.00033	0.000403	CcSEcCtD
Salbutamol—Pain—Epirubicin—pancreatic cancer	0.00033	0.000403	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000326	0.000398	CcSEcCtD
Salbutamol—Insomnia—Doxorubicin—pancreatic cancer	0.000323	0.000395	CcSEcCtD
Salbutamol—Paraesthesia—Doxorubicin—pancreatic cancer	0.000321	0.000392	CcSEcCtD
Salbutamol—Dyspnoea—Doxorubicin—pancreatic cancer	0.000319	0.000389	CcSEcCtD
Salbutamol—Feeling abnormal—Epirubicin—pancreatic cancer	0.000318	0.000389	CcSEcCtD
Salbutamol—Somnolence—Doxorubicin—pancreatic cancer	0.000318	0.000388	CcSEcCtD
Salbutamol—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000316	0.000386	CcSEcCtD
Salbutamol—Dyspepsia—Doxorubicin—pancreatic cancer	0.000315	0.000384	CcSEcCtD
Salbutamol—Decreased appetite—Doxorubicin—pancreatic cancer	0.000311	0.000379	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000309	0.000377	CcSEcCtD
Salbutamol—Fatigue—Doxorubicin—pancreatic cancer	0.000308	0.000376	CcSEcCtD
Salbutamol—Urticaria—Epirubicin—pancreatic cancer	0.000307	0.000375	CcSEcCtD
Salbutamol—Constipation—Doxorubicin—pancreatic cancer	0.000306	0.000373	CcSEcCtD
Salbutamol—Pain—Doxorubicin—pancreatic cancer	0.000306	0.000373	CcSEcCtD
Salbutamol—Abdominal pain—Epirubicin—pancreatic cancer	0.000305	0.000373	CcSEcCtD
Salbutamol—Body temperature increased—Epirubicin—pancreatic cancer	0.000305	0.000373	CcSEcCtD
Salbutamol—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000295	0.00036	CcSEcCtD
Salbutamol—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000292	0.000357	CcSEcCtD
Salbutamol—Hypersensitivity—Epirubicin—pancreatic cancer	0.000285	0.000348	CcSEcCtD
Salbutamol—Urticaria—Doxorubicin—pancreatic cancer	0.000284	0.000347	CcSEcCtD
Salbutamol—Abdominal pain—Doxorubicin—pancreatic cancer	0.000283	0.000345	CcSEcCtD
Salbutamol—Body temperature increased—Doxorubicin—pancreatic cancer	0.000283	0.000345	CcSEcCtD
Salbutamol—Asthenia—Epirubicin—pancreatic cancer	0.000277	0.000338	CcSEcCtD
Salbutamol—Pruritus—Epirubicin—pancreatic cancer	0.000273	0.000334	CcSEcCtD
Salbutamol—Diarrhoea—Epirubicin—pancreatic cancer	0.000264	0.000323	CcSEcCtD
Salbutamol—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000263	0.000322	CcSEcCtD
Salbutamol—Asthenia—Doxorubicin—pancreatic cancer	0.000256	0.000313	CcSEcCtD
Salbutamol—Dizziness—Epirubicin—pancreatic cancer	0.000255	0.000312	CcSEcCtD
Salbutamol—Pruritus—Doxorubicin—pancreatic cancer	0.000253	0.000309	CcSEcCtD
Salbutamol—Vomiting—Epirubicin—pancreatic cancer	0.000246	0.0003	CcSEcCtD
Salbutamol—Diarrhoea—Doxorubicin—pancreatic cancer	0.000245	0.000299	CcSEcCtD
Salbutamol—Rash—Epirubicin—pancreatic cancer	0.000244	0.000297	CcSEcCtD
Salbutamol—Dermatitis—Epirubicin—pancreatic cancer	0.000243	0.000297	CcSEcCtD
Salbutamol—Headache—Epirubicin—pancreatic cancer	0.000242	0.000296	CcSEcCtD
Salbutamol—Dizziness—Doxorubicin—pancreatic cancer	0.000236	0.000289	CcSEcCtD
Salbutamol—Nausea—Epirubicin—pancreatic cancer	0.000229	0.00028	CcSEcCtD
Salbutamol—Vomiting—Doxorubicin—pancreatic cancer	0.000227	0.000278	CcSEcCtD
Salbutamol—Rash—Doxorubicin—pancreatic cancer	0.000225	0.000275	CcSEcCtD
Salbutamol—Dermatitis—Doxorubicin—pancreatic cancer	0.000225	0.000275	CcSEcCtD
Salbutamol—Headache—Doxorubicin—pancreatic cancer	0.000224	0.000273	CcSEcCtD
Salbutamol—Nausea—Doxorubicin—pancreatic cancer	0.000212	0.000259	CcSEcCtD
Salbutamol—ADRB2—Signaling by GPCR—SSTR1—pancreatic cancer	0.000119	0.00282	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CNR1—pancreatic cancer	0.000117	0.00277	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—SSTR2—pancreatic cancer	0.000117	0.00277	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PPY—pancreatic cancer	0.000116	0.00276	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—GCG—pancreatic cancer	0.000115	0.00274	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—SSTR2—pancreatic cancer	0.000114	0.00271	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—GCG—pancreatic cancer	0.000113	0.00268	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCKBR—pancreatic cancer	0.000113	0.00268	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCKBR—pancreatic cancer	0.00011	0.00262	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—AGTR1—pancreatic cancer	0.00011	0.00261	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—AGTR1—pancreatic cancer	0.000108	0.00256	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GAST—pancreatic cancer	0.000107	0.00253	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GAST—pancreatic cancer	0.000104	0.00248	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—SCT—pancreatic cancer	0.000101	0.0024	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—SCT—pancreatic cancer	9.89e-05	0.00235	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GAST—pancreatic cancer	9.69e-05	0.0023	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CCK—pancreatic cancer	9.65e-05	0.00229	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GAST—pancreatic cancer	9.47e-05	0.00225	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CCK—pancreatic cancer	9.44e-05	0.00224	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GLP1R—pancreatic cancer	9.4e-05	0.00223	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CNR2—pancreatic cancer	9.4e-05	0.00223	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CCKAR—pancreatic cancer	9.25e-05	0.0022	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CNR2—pancreatic cancer	9.2e-05	0.00218	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GLP1R—pancreatic cancer	9.2e-05	0.00218	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—SCT—pancreatic cancer	9.18e-05	0.00218	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CCKAR—pancreatic cancer	9.05e-05	0.00215	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—SCT—pancreatic cancer	8.98e-05	0.00213	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRLHR—pancreatic cancer	8.78e-05	0.00209	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCK—pancreatic cancer	8.76e-05	0.00208	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRLHR—pancreatic cancer	8.59e-05	0.00204	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCK—pancreatic cancer	8.57e-05	0.00204	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CNR2—pancreatic cancer	8.54e-05	0.00203	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GLP1R—pancreatic cancer	8.54e-05	0.00203	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCKAR—pancreatic cancer	8.4e-05	0.00199	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CNR2—pancreatic cancer	8.35e-05	0.00198	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GLP1R—pancreatic cancer	8.35e-05	0.00198	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—IAPP—pancreatic cancer	8.33e-05	0.00198	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ZNRF3—pancreatic cancer	8.25e-05	0.00196	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ACVR1B—pancreatic cancer	8.25e-05	0.00196	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCKAR—pancreatic cancer	8.22e-05	0.00195	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—IAPP—pancreatic cancer	8.15e-05	0.00193	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ACVR1B—pancreatic cancer	8.07e-05	0.00192	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ZNRF3—pancreatic cancer	8.07e-05	0.00192	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PTHLH—pancreatic cancer	7.99e-05	0.0019	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PTHLH—pancreatic cancer	7.82e-05	0.00186	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—SHH—pancreatic cancer	7.66e-05	0.00182	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IAPP—pancreatic cancer	7.56e-05	0.0018	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—SHH—pancreatic cancer	7.49e-05	0.00178	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DTX1—pancreatic cancer	7.47e-05	0.00177	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SSTR3—pancreatic cancer	7.47e-05	0.00177	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IAPP—pancreatic cancer	7.4e-05	0.00176	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—SST—pancreatic cancer	7.31e-05	0.00174	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SSTR3—pancreatic cancer	7.3e-05	0.00173	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DTX1—pancreatic cancer	7.3e-05	0.00173	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PTHLH—pancreatic cancer	7.26e-05	0.00172	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PTCH1—pancreatic cancer	7.26e-05	0.00172	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SSTR1—pancreatic cancer	7.16e-05	0.0017	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—SST—pancreatic cancer	7.15e-05	0.0017	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PTHLH—pancreatic cancer	7.1e-05	0.00169	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PTCH1—pancreatic cancer	7.1e-05	0.00169	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PPY—pancreatic cancer	7.02e-05	0.00167	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SSTR1—pancreatic cancer	7e-05	0.00166	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SSTR2—pancreatic cancer	6.89e-05	0.00164	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PPY—pancreatic cancer	6.87e-05	0.00163	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CNR1—pancreatic cancer	6.75e-05	0.0016	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SSTR2—pancreatic cancer	6.74e-05	0.0016	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCKBR—pancreatic cancer	6.65e-05	0.00158	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—SST—pancreatic cancer	6.64e-05	0.00158	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	6.62e-05	0.00157	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CNR1—pancreatic cancer	6.6e-05	0.00157	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GCG—pancreatic cancer	6.52e-05	0.00155	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCKBR—pancreatic cancer	6.51e-05	0.00155	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—SST—pancreatic cancer	6.49e-05	0.00154	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	6.47e-05	0.00154	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GCG—pancreatic cancer	6.37e-05	0.00151	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DTX4—pancreatic cancer	6.26e-05	0.00149	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GLI1—pancreatic cancer	6.26e-05	0.00149	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AGTR1—pancreatic cancer	6.22e-05	0.00148	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CNR1—pancreatic cancer	6.13e-05	0.00146	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GLI1—pancreatic cancer	6.12e-05	0.00145	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DTX4—pancreatic cancer	6.12e-05	0.00145	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NRP1—pancreatic cancer	6.09e-05	0.00145	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PPP2R5B—pancreatic cancer	6.09e-05	0.00145	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AGTR1—pancreatic cancer	6.08e-05	0.00144	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CNR1—pancreatic cancer	5.99e-05	0.00142	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NRP1—pancreatic cancer	5.95e-05	0.00141	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PPP2R5B—pancreatic cancer	5.95e-05	0.00141	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GCG—pancreatic cancer	5.92e-05	0.00141	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HEY2—pancreatic cancer	5.86e-05	0.00139	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GCG—pancreatic cancer	5.79e-05	0.00137	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HEY2—pancreatic cancer	5.73e-05	0.00136	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GAST—pancreatic cancer	5.72e-05	0.00136	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AGTR1—pancreatic cancer	5.64e-05	0.00134	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GAST—pancreatic cancer	5.6e-05	0.00133	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AGTR1—pancreatic cancer	5.52e-05	0.00131	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SCT—pancreatic cancer	5.42e-05	0.00129	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HEY1—pancreatic cancer	5.42e-05	0.00129	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SCT—pancreatic cancer	5.31e-05	0.00126	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HEY1—pancreatic cancer	5.31e-05	0.00126	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCK—pancreatic cancer	5.17e-05	0.00123	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCK—pancreatic cancer	5.06e-05	0.0012	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CNR2—pancreatic cancer	5.04e-05	0.0012	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GLP1R—pancreatic cancer	5.04e-05	0.0012	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CXCL8—pancreatic cancer	5.04e-05	0.0012	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCKAR—pancreatic cancer	4.96e-05	0.00118	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CNR2—pancreatic cancer	4.93e-05	0.00117	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GLP1R—pancreatic cancer	4.93e-05	0.00117	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CXCL8—pancreatic cancer	4.93e-05	0.00117	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCKAR—pancreatic cancer	4.85e-05	0.00115	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JAG2—pancreatic cancer	4.81e-05	0.00114	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MEN1—pancreatic cancer	4.74e-05	0.00113	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JAG2—pancreatic cancer	4.71e-05	0.00112	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MEN1—pancreatic cancer	4.64e-05	0.0011	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SHH—pancreatic cancer	4.52e-05	0.00107	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH4—pancreatic cancer	4.49e-05	0.00107	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IAPP—pancreatic cancer	4.47e-05	0.00106	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SHH—pancreatic cancer	4.42e-05	0.00105	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH4—pancreatic cancer	4.4e-05	0.00104	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IAPP—pancreatic cancer	4.37e-05	0.00104	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTHLH—pancreatic cancer	4.29e-05	0.00102	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTCH1—pancreatic cancer	4.29e-05	0.00102	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTHLH—pancreatic cancer	4.19e-05	0.000996	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTCH1—pancreatic cancer	4.19e-05	0.000996	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SST—pancreatic cancer	3.92e-05	0.000932	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CG—pancreatic cancer	3.87e-05	0.000919	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JAG1—pancreatic cancer	3.84e-05	0.000912	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SST—pancreatic cancer	3.84e-05	0.000911	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH3—pancreatic cancer	3.82e-05	0.000908	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CG—pancreatic cancer	3.78e-05	0.000899	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JAG1—pancreatic cancer	3.75e-05	0.000892	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH3—pancreatic cancer	3.74e-05	0.000888	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CNR1—pancreatic cancer	3.62e-05	0.00086	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CNR1—pancreatic cancer	3.54e-05	0.000841	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CG—pancreatic cancer	3.51e-05	0.000834	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GCG—pancreatic cancer	3.5e-05	0.00083	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CG—pancreatic cancer	3.44e-05	0.000816	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GCG—pancreatic cancer	3.42e-05	0.000812	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CD—pancreatic cancer	3.4e-05	0.000808	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AGTR1—pancreatic cancer	3.33e-05	0.000792	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CD—pancreatic cancer	3.33e-05	0.00079	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STK11—pancreatic cancer	3.29e-05	0.000781	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AGTR1—pancreatic cancer	3.26e-05	0.000775	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STK11—pancreatic cancer	3.21e-05	0.000764	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PRSS1—pancreatic cancer	3.16e-05	0.000751	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CD—pancreatic cancer	3.09e-05	0.000733	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CD—pancreatic cancer	3.02e-05	0.000717	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.96e-05	0.000704	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.9e-05	0.000689	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SMAD4—pancreatic cancer	2.88e-05	0.000684	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CXCL8—pancreatic cancer	2.85e-05	0.000677	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SMAD4—pancreatic cancer	2.82e-05	0.000669	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HES1—pancreatic cancer	2.81e-05	0.000668	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CXCL8—pancreatic cancer	2.79e-05	0.000662	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HES1—pancreatic cancer	2.75e-05	0.000653	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ARG2—pancreatic cancer	2.74e-05	0.000651	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CB—pancreatic cancer	2.69e-05	0.000639	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CB—pancreatic cancer	2.63e-05	0.000625	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CXCL8—pancreatic cancer	2.59e-05	0.000614	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCL8—pancreatic cancer	2.53e-05	0.000601	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TERT—pancreatic cancer	2.46e-05	0.000585	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TERT—pancreatic cancer	2.41e-05	0.000572	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TYMP—pancreatic cancer	2.4e-05	0.000569	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HIF1A—pancreatic cancer	2.36e-05	0.000559	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TSC2—pancreatic cancer	2.35e-05	0.000558	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HIF1A—pancreatic cancer	2.3e-05	0.000547	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOE—pancreatic cancer	2.3e-05	0.000546	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TSC2—pancreatic cancer	2.3e-05	0.000546	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KDR—pancreatic cancer	2.25e-05	0.000535	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOE—pancreatic cancer	2.25e-05	0.000534	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KDR—pancreatic cancer	2.2e-05	0.000523	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	2.14e-05	0.000509	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	2.12e-05	0.000504	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	2.1e-05	0.000498	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	2.08e-05	0.000493	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	2.07e-05	0.000493	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	2.07e-05	0.000493	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGF—pancreatic cancer	2.05e-05	0.000487	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	2.03e-05	0.000482	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	2.03e-05	0.000482	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGF—pancreatic cancer	2.01e-05	0.000477	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.93e-05	0.000459	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.9e-05	0.000451	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	1.89e-05	0.000449	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	1.85e-05	0.000439	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	1.82e-05	0.000433	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.81e-05	0.000429	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.8e-05	0.000428	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	1.79e-05	0.000424	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	1.78e-05	0.000424	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.77e-05	0.00042	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	1.75e-05	0.000415	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.64e-05	0.00039	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	1.6e-05	0.000381	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	1.59e-05	0.000378	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	1.56e-05	0.000369	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	1.53e-05	0.000363	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	1.52e-05	0.000361	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	1.49e-05	0.000355	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	1.48e-05	0.000353	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	1.48e-05	0.000351	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	1.46e-05	0.000347	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	1.44e-05	0.000343	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	1.43e-05	0.00034	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	1.42e-05	0.000338	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	1.41e-05	0.000335	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CD44—pancreatic cancer	1.4e-05	0.000332	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	1.39e-05	0.000331	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	1.38e-05	0.000328	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	1.38e-05	0.000328	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	1.37e-05	0.000326	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	1.35e-05	0.000321	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	1.34e-05	0.000319	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	1.34e-05	0.000318	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GCG—pancreatic cancer	1.34e-05	0.000318	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	1.31e-05	0.000311	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SRC—pancreatic cancer	1.27e-05	0.000303	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—STK11—pancreatic cancer	1.26e-05	0.000299	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SRC—pancreatic cancer	1.25e-05	0.000296	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	1.24e-05	0.000295	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	1.23e-05	0.000292	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	1.23e-05	0.000291	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	1.21e-05	0.000288	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	1.2e-05	0.000286	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	1.2e-05	0.000285	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MYC—pancreatic cancer	1.14e-05	0.000271	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	1.14e-05	0.000271	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MYC—pancreatic cancer	1.12e-05	0.000265	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	1.12e-05	0.000265	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	1.11e-05	0.000265	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	1.09e-05	0.000259	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.08e-05	0.000257	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	1.05e-05	0.000251	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	1.03e-05	0.000245	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	9.69e-06	0.00023	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	9.48e-06	0.000225	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TP53—pancreatic cancer	9.38e-06	0.000223	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TP53—pancreatic cancer	9.17e-06	0.000218	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	8.97e-06	0.000213	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOE—pancreatic cancer	8.81e-06	0.000209	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	8.77e-06	0.000208	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	7.95e-06	0.000189	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	7.92e-06	0.000188	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	7.74e-06	0.000184	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARG—pancreatic cancer	7.67e-06	0.000182	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	6.99e-06	0.000166	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	6.09e-06	0.000145	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS2—pancreatic cancer	6.03e-06	0.000143	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTEN—pancreatic cancer	5.26e-06	0.000125	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	3.71e-06	8.82e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.03e-06	7.2e-05	CbGpPWpGaD
